Institute submits NDA for PET to diagnose Parkinsonian syndromes

11/15/2012 | MedicalXpress.com

The Feinstein Institute for Medical Research said it has submitted a new-drug application to the FDA for the use of 18F-fluorodopa-PET in diagnosing Parkinsonian syndromes. The FDA earlier this year approved the institute's use of the scan as part of an expanded access investigational new drug program.

View Full Article in:

MedicalXpress.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD